Exparel 133 MG/10 ML vial 10ML
Ended Awarded
- Contract number
- SPE2DB25FQAJS
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,046
Award facts
- Contract value 100% obligated
- $3,046.10 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $3,046.10 by the Defense Logistics Agency on September 18, 2025, for the supply of EXPAREL 133 mg/10 mL vials. The contract, which carries no set-aside designation, is scheduled for completion by October 9, 2025, with performance to take place in Park Ridge, Illinois. This delivery order represents a discrete purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, a comprehensive pharmaceutical supply agreement valued at approximately $500 million and valid through November 2026.
EXPAREL is a liposomal bupivacaine local anesthetic used for infiltration and nerve blocks in surgical settings, making this procurement consistent with the Defense Logistics Agency's responsibility to supply pharmaceutical products supporting military healthcare facilities worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, maintaining a robust portfolio of delivery orders for an extensive range of branded and generic medications, biologics, and medical consumables to Department of Defense healthcare sites. The company's consistent success in federal procurement demonstrates its capability to reliably deliver specialized pharmaceutical products to support military medical operations globally.
Quick answers
Who was awarded contract SPE2DB25FQAJS?
SPE2DB25FQAJS was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 18, 2025.
How much is contract SPE2DB25FQAJS worth?
The government has obligated $3,046 on SPE2DB25FQAJS.
Is contract SPE2DB25FQAJS an order under another contract?
Yes. SPE2DB25FQAJS is a delivery order under SPE2DB25D9305, an indefinite delivery contract.
Was contract SPE2DB25FQAJS competed?
The extent of competition for SPE2DB25FQAJS was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award